Briacell Therapeutics Corp's shares surged by nearly 2% in the latest trading session, reflecting positive investor sentiment.
Briacell Therapeutics Corp (BCT.TO) experienced a notable gain of 1.89% in the last trading session, closing at CA$4.31. This uptick marks a positive shift for the biotech firm, which has been navigating a challenging market landscape. Investors are keenly watching the company's developments as it continues to innovate in the field of personalized immunotherapy.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$48.54M
52W high
$27.20
52W low
$3.68
1W change
+6.60%
Beta
1.54
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 275.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+275.2% Upside
Current Price
C$5.33
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
64.8%
Annualized
90-Day Vol
87.4%
Annualized
Trend (90d)
-43.4%
Annualized drift
90d Mean
C$4.56
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.06 | C$4.05 โ C$6.33 |
| 60 trading days | C$4.81 | C$3.50 โ C$6.59 |
| 90 trading days | C$4.56 | C$3.10 โ C$6.72 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: With a market cap of CA$37.2 million and no current dividend yield, Briacell remains a speculative investment. However, the recent share price increase could signal renewed interest in its therapeutic advancements.
Briacell Therapeutics Corp gains 1.89% in one day
The stock closed at CA$4.31, reflecting a market cap of CA$37.2 million, indicating the company's ongoing struggle for profitability in a competitive market.
Bull case
The recent rise in Briacell's stock likely reflects growing investor confidence in its innovative therapies, especially after some recent clinical successes. As the company continues to develop its personalized immunotherapy solutions, potential breakthroughs could attract even more interest and investment.
Bear case
Despite the gains, Briacell still faces significant challenges, including a lack of profitability and ongoing market volatility in the biotech sector. Investors should be cautious, as the stock's performance can be highly sensitive to clinical trial outcomes and regulatory approvals.
Stock Performance Overview
Briacell Therapeutics Corp's stock has shown resilience with a 1.89% increase in the last trading session. Closing at CA$4.31, this movement indicates a positive shift in investor sentiment, particularly as the company continues to focus on its innovative therapies.
Market Position and Future Outlook
With a market cap of CA$37.2 million, Briacell is still in a precarious position within the biotech landscape. Investors are advised to keep a close eye on the company's upcoming developments, particularly regarding its personalized immunotherapy products, which could dictate future stock performance.
Advertisement
